Key Points
- Sandra Calvin, Travere's CAO, sold 21,977 shares on April 14 at an average price of $41.07 for about $902,595; the sale—executed under a Rule 10b5‑1 plan—left her with 42,353 shares, a 34.16% reduction in her position.
- The transaction occurs amid a broader uptick in sentiment after the FDA full approval of Filspari and multiple analyst upgrades, but heavy insider selling could add near‑term downward pressure and increase volatility despite higher price targets.
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 7,215 shares of the business's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $41.93, for a total transaction of $302,524.95. Following the completion of the transaction, the insider owned 138,608 shares in the company, valued at approximately $5,811,833.44. The trade was a 4.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Peter Heerma also recently made the following trade(s):
- On Tuesday, February 3rd, Peter Heerma sold 7,310 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total value of $234,797.20.
Travere Therapeutics Stock Down 3.4%
Travere Therapeutics stock opened at $39.54 on Friday. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The firm's fifty day moving average is $29.77 and its 200 day moving average is $31.42. The company has a market capitalization of $3.65 billion, a PE ratio of -131.80 and a beta of 0.86. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $43.31.
Key Travere Therapeutics News
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: FDA grants full approval for Filspari in FSGS, materially expanding Travere’s rare‑kidney franchise and adding an estimated ~30,000 U.S. patients to the addressable market — the core reason for the earlier, large share price gain. Filspari approval article
- Positive Sentiment: Market reaction and analyst upgrades lifted sentiment and targets (examples: Canaccord, Guggenheim, Piper Sandler, HC Wainwright), reinforcing a re‑rating narrative and supporting higher medium‑term revenue expectations for Filspari. Guggenheim note
- Neutral Sentiment: Trading activity is elevated and options volumes spiked around the approval — this amplifies short‑term moves (both up and down) and suggests greater volatility while the market digests label details and early commercialization assumptions. Options activity report
- Neutral Sentiment: Company commentary and coverage (conference/transcript writeups, health press) are clarifying the label and launch plans, but concrete revenue/volume reads are not yet available — useful for modeling but not definitive. Company discussion
- Negative Sentiment: Multiple insiders (CEO, directors, CFO, other executives) sold material blocks of shares over the last two trading days — most sales were executed under pre‑arranged Rule 10b5‑1 plans or to cover taxes related to vesting, but the scale of selling can fuel near‑term downward pressure and signal profit‑taking after the approval‑driven rally. Example SEC filing for CEO sale. CEO Form 4
- Negative Sentiment: Some analysts warn that estimate‑revision trends and elevated expectations could limit near‑term upside — the stock may consolidate or pull back as investors re‑rate forward revenue assumptions. Zacks caution
Wall Street Analyst Weigh In
TVTX has been the subject of a number of recent analyst reports. Citigroup upped their price objective on shares of Travere Therapeutics from $48.00 to $53.00 and gave the stock a "buy" rating in a research report on Tuesday. Weiss Ratings restated a "sell (e+)" rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Canaccord Genuity Group raised their price target on Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a report on Tuesday. Guggenheim upped their target price on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wall Street Zen lowered Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $42.50.
Check Out Our Latest Report on TVTX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of TVTX. Emerald Advisers LLC grew its position in Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock worth $51,308,000 after acquiring an additional 55,407 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in Travere Therapeutics in the 3rd quarter worth $3,872,000. Palisades Investment Partners LLC bought a new stake in Travere Therapeutics during the 4th quarter valued at approximately $5,264,000. Voya Investment Management LLC lifted its position in Travere Therapeutics by 16.2% in the 3rd quarter. Voya Investment Management LLC now owns 194,854 shares of the company's stock valued at $4,657,000 after acquiring an additional 27,133 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new stake in shares of Travere Therapeutics in the 3rd quarter worth $3,095,000.
About Travere Therapeutics
(
Get Free Report)
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
